Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pandemic flu H5 HA mRNA SD2 vaccine
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The pandemic flu H5 HA mRNA SD2 vaccine is a prophylactic, second-generation, structurally designed messenger RNA (mRNA) vaccine developed to protect against avian influenza A(H5N1). The vaccine encodes the hemagglutinin (HA) glycoprotein of the H5 subtype, which is a major surface antigen of the influenza virus and a key target for neutralizing antibodies. Upon administration, the mRNA is taken up by host cells and translated into the viral HA protein, stimulating an immune response that includes both antibody production and T cell activation. This immunostimulant mechanism aims to provide protection against infection with circulating or emerging strains of H5N1 influenza. The primary indication for this vaccine is prevention of disease caused by avian influenza A(H5N1), particularly in preparation for or during pandemics[1][3][4].
- Other names
- pandemic flu H5 HA mRNA SD2 vaccine
02
Targets
Translation factors (Translation initiation/elongation factors)H5 HA (Influenza A hemagglutinin H5)
Beyond the preview
Go deeper on pandemic flu H5 HA mRNA SD2 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pandemic flu H5 HA mRNA SD2 vaccine.